Novartis (NVS) says that the latest results from two Phase III clinical trials further the...
Monday, December 10, 2012, 5:29 PM ETNovartis (NVS) says that the latest results from two Phase III clinical trials further the benefits of Tasigna over Glivec tablets for the treatment of Philadelphia chronic myeloid leukemia. Patients using Tasigna achieved significantly deeper molecular response versus Glivec, and the data suggests a correlation between early molecular response at three and six months and survival outcome for newly diagnosed patients.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles